Skip to content

Study · Case report or series · n = 1 · 2024

1 result

Life-Threatening Anaphylaxis due to Cerebrolysin®.

Trimmel H, Tauber W, Zikeli M

Case reports in neurological medicine18 Jul 2024Cited by 1 (Europe PMC)

PMID39055722 (opens in a new tab)PMCIDPMC11272398 (opens in a new tab)DOI10.1155/2024/2332908 (opens in a new tab)PepBankPUB-39055722
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

In this case report, we describe a well-documented, severe anaphylactic reaction after intravenous administration of cerebrolysin, a neurotrophic agent derived from highly purified porcine brain tissue, consisting of peptides and free amino acids. Cerebrolysin has been in use for decades, in various neurological diseases, but especially stroke and traumatic brain injury, with the aim of enhancing cognitive performance. After administration of cerebrolysin to an 85-year-old male patient suffering from subacute stroke, he developed a fulminant anaphylactic reaction. Following institutional standards, vital functions were quickly restored. The anaphylactic reaction was clearly confirmed by laboratory tests. To date, only rare cases of anaphylaxis due to cerebrolysin have been published in the literature. The current report is intended to raise awareness for the possibility of such a reaction, given the widespread use of cerebrolysin in several indications in mostly critical patients. The case shows how a completely unexpected life-threatening situation can be successfully treated by targeted measures, if the situation is recognized quickly. In light of this event, we consider pathophysiology of allergic reactions and treatment guidelines.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In an 85-year-old man with subacute stroke, cerebrolysin administration was followed by fulminant anaphylaxis confirmed by laboratory tests.

    In plain wordsIn a man with subacute stroke, cerebrolysin administration was followed by severe anaphylaxis confirmed by laboratory tests.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableSevere anaphylaxis
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    After administration of cerebrolysin to an 85-year-old male patient suffering from subacute stroke, he developed a fulminant anaphylactic reaction.
    2 context sentences
    Summary · context
    The anaphylactic reaction was clearly confirmed by laboratory tests.
    Summary · context
    In this case report, we describe a well-documented, severe anaphylactic reaction after intravenous administration of cerebrolysin, a neurotrophic agent derived from highly purified porcine brain tissue, consisting of peptides and free amino acids.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.